1. Home
  2. FPH vs RIGL Comparison

FPH vs RIGL Comparison

Compare FPH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FPH
  • RIGL
  • Stock Information
  • Founded
  • FPH 2009
  • RIGL 1996
  • Country
  • FPH United States
  • RIGL United States
  • Employees
  • FPH N/A
  • RIGL N/A
  • Industry
  • FPH Real Estate
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • FPH Finance
  • RIGL Health Care
  • Exchange
  • FPH Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • FPH 390.0M
  • RIGL 335.5M
  • IPO Year
  • FPH 2017
  • RIGL 2000
  • Fundamental
  • Price
  • FPH $5.68
  • RIGL $38.85
  • Analyst Decision
  • FPH
  • RIGL Buy
  • Analyst Count
  • FPH 0
  • RIGL 5
  • Target Price
  • FPH N/A
  • RIGL $38.20
  • AVG Volume (30 Days)
  • FPH 150.3K
  • RIGL 995.6K
  • Earning Date
  • FPH 10-16-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • FPH N/A
  • RIGL N/A
  • EPS Growth
  • FPH 46.82
  • RIGL N/A
  • EPS
  • FPH 1.08
  • RIGL 5.43
  • Revenue
  • FPH $197,429,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • FPH N/A
  • RIGL $59.93
  • Revenue Next Year
  • FPH N/A
  • RIGL N/A
  • P/E Ratio
  • FPH $5.28
  • RIGL $7.15
  • Revenue Growth
  • FPH N/A
  • RIGL 105.62
  • 52 Week Low
  • FPH $3.10
  • RIGL $12.66
  • 52 Week High
  • FPH $6.71
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • FPH 56.60
  • RIGL 68.57
  • Support Level
  • FPH $5.51
  • RIGL $39.00
  • Resistance Level
  • FPH $5.77
  • RIGL $42.08
  • Average True Range (ATR)
  • FPH 0.14
  • RIGL 2.32
  • MACD
  • FPH 0.04
  • RIGL -0.37
  • Stochastic Oscillator
  • FPH 95.83
  • RIGL 53.26

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: